SP 8008
Alternative Names: SP-8008Latest Information Update: 28 Nov 2022
At a glance
- Originator Seoul National University; Shin Poong Pharmaceutical
- Developer Shin Poong Pharmaceutical
- Class Benzoic acids; Cardiovascular therapies; Vascular disorder therapies
- Mechanism of Action Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Acute coronary syndromes; Stroke
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for phase-I development in Acute coronary syndromes(In volunteers) in United Kingdom (PO, Capsule)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Stroke(In volunteers) in United Kingdom (PO, Capsule)
- 25 Feb 2021 SP 8008 is available for licensing as of 03 Mar 2021. https://shinpoong.co.kr/en/sub3/3_4.php (Shin Poong Pharmaceuticals Website, March 2021)